loader2
Login Open ICICI 3-in-1 Account

Hester Biosciences Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Hester Biosciences Ltd. 12 Nov 2025 13:41 PM

Q2FY26 Quarterly Result Announced for Hester Biosciences Ltd.

Pharmaceuticals company Hester Biosciences announced Q2FY26 results

  • Revenue from operations: Rs 709.69 million against Rs 836.92 million during Q2FY25, change -15%.
  • EBITDA: Rs 235.97 million against Rs 219.55 million during Q2FY25, change 7%.
  • EBITDA Margin: 33% for Q2FY26.
  • PAT: Rs 143.31 million against Rs 83.91 million during Q2FY25, change 71%.
  • PAT Margin: 20% for Q2FY26.
  • EPS: Rs 16.85 for Q2FY26.

Result PDF

Pharmaceuticals company Hester Biosciences announced Q1FY26 results

  • Revenue from operations: Rs 841.05 million compared to Rs 822.67 million during Q1FY25, change 2%.
  • EBITDA: Rs 261.79 million compared to Rs 197.35 million during Q1FY25, change 33%.
  • EBITDA Margin: 31% for Q1FY26.
  • PAT: Rs 172.96 million compared to Rs 74.86 million during Q1FY25, change 131%.
  • EPS: Rs 20.33 for Q1FY26.
  • Animal Healthcare Division: In Q1FY26, the division recorded a 33% decline in sales, primarily due to timing delays in key government Immunisation programmes for PPR and Lumpy Skin Disease, in which Hester’s PPR and Goat Pox vaccines respectively, are widely used, have got delayed.
  • Poultry Healthcare Division: The Poultry Healthcare Division recorded a 2% growth in Q1FY26, led by robust demand for key vaccines, particularly for Newcastle Disease and Marek’s Disease.

Result PDF

Pharmaceuticals company Hester Biosciences announced Q4FY25 results

  • Revenue from operations: Rs 819.25 million compared to Rs 792.55 million during Q4FY24, change 3%.
  • Gross Profit Margin: Rs 611.83 million compared to Rs 577.16 million during Q4FY24, change 6%.
  • EBITDA: Rs 135.41 million compared to Rs 205.48 million during Q4FY24, change -34%.
  • EBITDA margin: 17% for Q4FY25.
  • PAT: Rs 15.41 million compared to Rs 63.95 million during Q4FY24, change -76%.
  • PAT margin: 2% for Q4FY25.

Result PDF

Pharmaceuticals company Hester Biosciences announced Q3FY25 results

  • Divisional Product Sales: Rs 632.18 million, down 6% YoY from Rs 669.83 million
  • Revenue from Operations: Rs 632.18 million, down 6% YoY from Rs 669.83 million
    • Hester Nepal: Rs 8.09 million, up 2% YoY from Rs 7.91 million
    • Hester Africa: Rs 8.05 million, up 11% YoY from Rs 7.26 million
  • Gross Profit Margin: Rs 435.93 million, down 6% YoY from Rs 463.44 million
  • EBITDA: Rs 138.45 million, up 12% YoY from Rs 123.53 million
  • EBITDA %: 22%, up 4% YoY from 18%
  • PAT: Rs 114.08 million, up 184% YoY from Rs 40.20 million
  • PAT %: 18%, up 12% YoY from 6%
  • EPS: Rs 13.41, up 184% YoY from 4.73

Result PDF

Pharmaceuticals company Hester Biosciences announced Q2FY25 results

  • Revenue from operations: Rs 836.92, compared to Q2FY24 Rs 704.55 change 19%.
  • Consolidated EBITDA: Rs 219.55 million change 15%
  • Q2FY25 Consolidated Divisional Product sales up by 21% & Profit up by 108%.
  • Hester Nepal achieved net profit of Rs 0.29 million in Q2FY25, reversing from a loss of Rs 7.05 million in Q2FY24. The subsidiary fulfilled export orders from government tenders and met domestic vaccine demand, showcasing its growth potential. Hester Nepal remains debt-free with strong cash flows from the quarter.
  • Hester Africa reduced its net loss to Rs 23.67 million in Q2FY25, down from net loss of Rs 49.17 million in Q2FY24. Hester Africa is actively participating in international tenders and meeting trade demands across various African countries, with increasing awareness and demand for vaccines.

Result PDF

Pharmaceuticals company Hester Biosciences announced Q1FY25 results:

  • Q1FY25 Standalone Divisional Product sales up by 37% & Profit up by 30%
  • Q1FY25 Consolidated Divisional Product sales up by 35% & Profit up by 9%
  • The divisional performance has demonstrated growth in the current quarter compared to Q1FY24, with sales increasing by 37%.
  • The overall sales show a decrease of 9% QoQ, primarily attributed to the one-time sales of other pharmaceutical products in Q1FY24.
  • Hester focused on higher-margin products and solutions in Q1FY25, leading to a significant rise in gross profit margin from 57% to 69%.
  • Increased revenue from divisional product sales allowed for better absorption of fixed costs, resulting in a 5% improvement in EBITDA%.
  • Overall absolute PAT increased by 30% and PAT% ratio increased by 3%, reflecting improved operational efficiency.

Result PDF

Pharmaceuticals company Hester Biosciences announced Q4FY24 & FY24 results:

Financial Highlights:

  • Hester Biosciences reported an increase in standalone revenue by 20% and consolidated revenue by 18% in Q4FY24 compared to the previous year.
  • The audited financial results for Q4 & FY24 show the company's resilience with a recommendation for a dividend of 6 per equity share of Rs 10 each (60%) for FY24, awaiting shareholder approval.
  • The company has reduced its borrowing by 19% and increased cash generated from operations by 28% during the year.
  • Overall gross profit margin in Q4FY24 increased by 1% compared to Q4FY23, primarily due to the increase in the proportion of vaccines from 60% to 75% in Q4FY24.
  • In Q4FY24, EBITDA increased by 14% in alignment with a growth in sales, resulting in a 19% increase in PAT for the quarter.
  • The total borrowings of the Company has reduced by Rs 307.58 million (19%) during the year.
  • The cash generated from operations has increased by Rs 94.50 million (28%) during the year

Animal Healthcare Division:

  • The Animal Healthcare division saw a growth of 89% in Q4FY24, driven by sales of Goat Pox vaccine and vaccines for a government immunisation program.
  • Despite regulatory challenges, the Animal Healthcare division has demonstrated the ability to recover and sustain growth.

Poultry Healthcare Division:

  • The Poultry Healthcare division achieved a notable growth of 22% in Q4FY24, with a consistent upward trend throughout the year.
  • Strategic introductions of new products and leveraging market opportunities have been instrumental in the division's sales performance.

Petcare Division:

  • In Q4FY24, the Petcare division saw a minor decrease in sales from the previous quarter but reported a notable annual growth of 49%.
  • The Petcare division's focus on building a strong foundation and delivering high-quality products is reflected in its substantial growth.

Result PDF

Pharmaceuticals company Hester Biosciences announced Q2FY24 & H1FY24 results:

1. Financial Performance:

  • Q2FY24:
    • Revenue from Operations: Rs 704.55 crore, down 4% YoY
    • EBITDA: Rs 132.12 crore, up 4% YoY
    • Profit after Tax (excl. OCI): Rs 40.41 crore, down 39% YoY
    • Earnings Per Share (EPS): Rs 4.75, down 39% YoY
  • H1FY24:
    • Revenue from Operations: Rs 1,583.08 crore, up 28% YoY
    • EBITDA: Rs 275.75 crore, up 37% YoY
    • Profit after Tax (excl. OCI): Rs 107.51 crore, up 6% YoY
    • Earnings Per Share (EPS): Rs 12.64, up 6% YoY

2. Division Performance:
-  Animal Healthcare division experienced a 16% decline in sales in Q2FY24 due to uneven sales of the Goat Pox Vaccine.
- Poultry Healthcare division saw a 4% decrease in overall sales in Q2FY24, with a growth in domestic vaccine sales, but a reduction in export sales.
- Petcare division achieved impressive performance, growing 98% in Q2FY24.

3. Subsidiary Performance:
- Hester Nepal had a turnover of Rs 7.28 million in Q2FY24, primarily from domestic sales of vaccines, with an overall net loss of Rs 7.05 million.
- Hester Africa continued export sales but faced an overall loss of Rs 49.17 million due to foreign exchange fluctuations.
- Hester's share of profit in the joint venture entity, Thrishool Exim Limited (Tanzania), increased by 9.86 million in Q2FY24.

 

 

Result PDF

Pharmaceuticals company Hester Biosciences announced Q4FY23 & FY23 results:

Standalone Q4FY23 & FY23:

  • Overall gross profit margin reduced by 1% due to the change in product mix between vaccines and health products, health products sales having gone up.
  • Operating EBITDA increased with the increase in sales.
  • The reduction in EBITDA margin was due to the reduction in Gross Profit margin, accompanied by higher market development costs in animal health division and the new pet division
  • Q4 PAT margin benefited from lower finance costs due to the reversal of unrealized forex loss of Rs 6.46 million on the translation of USD loan in Q4FY23, as against a loss of Rs 5.31 million in Q4FY22. Consequently, PAT increased by 27% from Rs 49.48 million to Rs 62.63 million.

 

Result PDF

Pharmaceuticals firm Hester Biosciences announced Q3FY23 results:

  • Standalone Q3FY23 results:
    • Gross margins:
      • There has been an improvement in the margins of health products in poultry healthcare and animal healthcare divisions.
      • There has been a write-off of Rs 16 million of expired vaccine stocks in the poultry healthcare division.
      • The overall impact has been a reduction of gross margins by 3% in Q3.
    • PAT margin declined due to unrealized MTM losses of Rs 24.40 million on the translation of US $ loan, included in finance costs.
  • Consolidated Q3FY23:
    • Results also include operations of subsidiaries in Nepal and Tanzania.
    • Hester Nepal had a turnover of Rs 52.62 million with an overall net profit of Rs 24.87 million during Q3FY23.
    • Profit in Q3 grew with the improved profitability of Hester India, Hester Nepal and Hester’s share in the joint venture entity, Thrishool Exim Limited.
    • In Hester Africa, market authorization has been received from Tanzania Medicines and Medical Devices Authority (TMDA) for two important ruminant vaccines, Lumpy Skin Disease and CBPP.
    • Hester Nepal has received a manufacturing license and marketing authorization for two additional vaccines, Live LASMAS and Inactivated Coryza .

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app